

CITATION REPORT

List of articles citing

Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antag

DOI: 10.1002/jcph.1689

Journal of Clinical Pharmacology, 2020, 60, 1606-1616.

Source: <https://exaly.com/paper-pdf/75631064/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 427-437	3.8	6
8	OriaHnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids. <i>Annals of Pharmacotherapy</i> , 2022 , 56, 93-101	2.9	2
7	Analytical methodology and pharmacokinetic study of elagolix in plasma of rats using a newly developed UPLC-MS/MS assay. <i>Arabian Journal of Chemistry</i> , 2021 , 14, 103235	5.9	2
6	Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.. <i>BMC Women's Health</i> , 2022 , 22, 14	2.9	0
5	Effects of Elagolix on the Pharmacokinetics of Omeprazole and its Metabolites in Healthy Premenopausal Women.. <i>Clinical and Translational Science</i> , 2022 ,	4.9	
4	Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. <i>Clinical Pharmacokinetics</i> , 2021 , 61, 577	6.2	
3	Isotretinoin and its metabolites alter mRNA of multiple enzyme and transporter genes in vitro but downregulation of OATP1B1 does not translate to the clinic.. <i>Drug Metabolism and Disposition</i> , 2022 ,	4	
2	Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling. 2023 , 25,		0
1	Combined oral contraceptives as victims of drug interactions. DMD-MR-2022-000854		0